Tetraphase up on Phase III cUTI data

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) was up $1.93 (15%) to $15.01 on Wednesday after reporting data from the lead-in portion of the Phase III IGNITE 2 trial of eravacycline to treat complicated urinary tract infection (cUTI).

Patients receiving eravacycline had higher rates of microbiological eradication at the test-of-cure visit 6-8 days post-treatment compared with levofloxacin. The lead-in portion was not designed to show statistical significance. The study's pivotal stage is due to start in 4Q14 and data are expected in mid-2016. ...